Skip to search formSkip to main contentSkip to account menu

alectinib

Known as: 5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-, 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile 
An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration… 
National Institutes of Health

Related topics

Related topics

9 relations

Narrower (3)

AF802Alecensaalectinib hydrochloride

Broader (1)

CH5424802
Kinase Inhibitors [MoA]NCIt Antineoplastic Agent TerminologyRO5424802Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC
Abstract Background We report mature PFS, updated OS and safety data from the global phase III ALEX study (NCT02075840) of ALC vs… 
2018
2018
Brigatinib in Patients with Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer: A Retrospective Study.
2018
2018
Identification of NMU as a potential gene conferring alectinib resistance in non-small cell lung cancer based on bioinformatics analyses.
Review
2017
Review
2017
Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.
LBA9008Background: Alectinib, a TKI targeting ALK, has shown robust efficacy in crizotinib-naive/resistant ALK+ NSCLC. J-ALEX… 
2017
2017
Updated efficacy and safety of the j-alex study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naïve ALK fusion positive non-small cell lung cancer (ALK+ NSCLC).
9064Background: ALC is a highly selective, CNS-active ALK tyrosine kinase inhibitor. In the J-ALEX study, ALC proved superior… 
2016
2016
Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?
A study reported in this issue of The Oncologist examined the utility of next-generation sequencing (NGS) in detecting ALK… 
2016
2016
Alectinib’s activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series
In the present study we assessed the activity of the next-generation anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor… 
2016
2016
Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA.
2015
2015
Interstitial lung disease induced by alectinib (CH5424802/RO5424802).
A 75-year-old woman with anaplastic lymphoma kinase (ALK)-rearranged Stage IV lung adenocarcinoma was administered the selective… 
2015
2015
A phase I/II study with a CNS-penetrant, selective ALK inhibitor alectinib in ALK-rearranged non-small cell lung cancer (ALK+ NSCLC) patients (pts): Updates on progression free survival (PFS) and…
8061 Background: Alectinib, a CNS-penetrant, selective ALK inhibitor with a novel scaffold, was granted approval in Japan 2014… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)